Antisense oligodeoxynucleotides to latent membrane protein 1 induce growth inhibition, apoptosis and Bcl‐2 suppression in Epstein‐Barr virus (EBV)‐transformed B‐lymphoblastoid cells, but not in EBV‐positive natural killer cell lymphoma cells

Epstein‐Barr virus (EBV)‐encoded latent membrane protein 1 (LMP‐1) is essential for immortalization of B cells by EBV, protects the infected cells from apoptotic cell death and induces Bcl‐2 expression. Suppression of LMP‐1 expression by antisense oligodeoxynucleotides (AS‐oligo) to LMP‐1 inhibits proliferation, promotes apoptosis and suppresses Bcl‐2 expression in EBV‐transformed B cells. However, the function of LMP‐1 expression in EBV‐positive natural killer (NK) cell lymphoma cells has not been reported previously. We examined the function of LMP‐1 in two EBV‐positive NK cell lymphoma cell lines (NK‐YS and YT) through suppressing LMP‐1 expression by AS‐oligo to LMP‐1. The AS‐oligo to LMP‐1 suppressed LMP‐1 mRNA and protein expression in two EBV‐positive NK cell lymphoma cell lines, as well as in an EBV‐transformed B‐cell line (CMG‐1). Proliferation was inhibited, apoptosis was induced and Bcl‐2 expression was suppressed in CMG‐1 cells, but none of these events were observed in NK‐YS or YT cells. These results suggest that proliferation, inhibition of apoptosis and Bcl‐2 expression in EBV‐positive NK cell lymphoma cells are not directly regulated by LMP‐1 as in EBV‐transformed B‐cell lines, but are probably mediated through other signal transducing systems.

[1]  C. Meijer,et al.  No direct role for Epstein‐Barr virus in oral carcinogenesis: A study at the DNA, RNA and protein levels , 2000, International journal of cancer.

[2]  K. Ohshima,et al.  Nasal lymphomas in Japan: a high prevalence of Epstein-Barr virus type A and deletion within the latent membrane protein gene. , 1999, Leukemia & lymphoma.

[3]  S. Dirnhofer,et al.  High prevalence of a 30-base pair deletion in the Epstein-Barr virus (EBV) latent membrane protein 1 gene and of strain type B EBV in Mexican classical Hodgkin's disease and reactive lymphoid tissue. , 1999, Human pathology.

[4]  M. Ueffing,et al.  Latent membrane protein 1 of Epstein–Barr virus interacts with JAK3 and activates STAT proteins , 1999, The EMBO journal.

[5]  L. Young,et al.  Epstein-Barr Virus-Encoded Latent Membrane Protein 1 Activates the JNK Pathway through Its Extreme C Terminus via a Mechanism Involving TRADD and TRAF2 , 1999, Journal of Virology.

[6]  J. Lacy,et al.  Antisense to the epstein-barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. , 1998, Blood.

[7]  T. Yoshino,et al.  Characterization of a Novel Human Natural Killer-Cell Line (NK-YS) Established From Natural Killer Cell Lymphoma/Leukemia Associated With Epstein-Barr Virus Infection , 1998 .

[8]  W. Hammerschmidt,et al.  Epstein–Barr virus‐mediated B‐cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor , 1998, The EMBO journal.

[9]  A. Eliopoulos,et al.  Epstein–Barr virus: LMP1 masquerades as an active receptor , 1998, Current Biology.

[10]  T. Yoshino,et al.  Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein-Barr virus infection. , 1998, Blood.

[11]  W. Kolch,et al.  Epstein–Barr virus latent membrane protein‐1 triggers AP‐1 activity via the c‐Jun N‐terminal kinase cascade , 1997, The EMBO journal.

[12]  P. Quesenberry,et al.  The 30-bp deletion variant of Epstein-Barr virus-encoded latent membrane protein-1 prevails in acute infectious mononucleosis. , 1997, The Journal of infectious diseases.

[13]  M. Ueffing,et al.  Latent membrane protein 1 of Epstein–Barr virus mimics a constitutively active receptor molecule , 1997, The EMBO journal.

[14]  D. Baltimore,et al.  Localization of the Major NF-κB-activating Site and the Sole TRAF3 Binding Site of LMP-1 Defines Two Distinct Signaling Motifs* , 1997, The Journal of Biological Chemistry.

[15]  M. Sandberg,et al.  Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3 , 1997, Journal of virology.

[16]  E. Jaffe,et al.  Prevalence of Epstein-Barr viral sequences and EBV LMP1 oncogene deletions in Burkitt's lymphoma from Pakistan: epidemiological correlations. , 1997, Human pathology.

[17]  A. Carbone,et al.  Epstein-Barr virus strains with latent membrane protein-1 deletions: prevalence in the Italian population and high association with human immunodeficiency virus-related Hodgkin's disease. , 1997, Blood.

[18]  E. Kieff,et al.  Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation , 1997, Journal of virology.

[19]  E. Kieff,et al.  Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation , 1996, Molecular and cellular biology.

[20]  G. Srivastava,et al.  Nasal NK‐ and T‐cell lymphomas share the same type of Epstein‐Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease , 1996, International journal of cancer.

[21]  E. Kieff,et al.  Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  E. Jaffe,et al.  Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus--associated lymphoproliferative disorders and malignant lymphomas , 1996 .

[23]  P. Murray,et al.  BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders. , 1996, Blood.

[24]  E. Kieff Epstein-Barr virus and its replication , 1996 .

[25]  S. Jiang,et al.  Bcl-2 is expressed in human natural killer cells and is regulated by interleukin-2. , 1996, Natural immunity.

[26]  E. Jaffe,et al.  Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus--associated lymphoproliferative disorders and malignant lymphomas. , 1996, Blood.

[27]  Yi-Song Wang,et al.  The EBV-encoded LMP1 protein inhibits p53-triggered apoptosis but not growth arrest. , 1995, Oncogene.

[28]  F. Ho,et al.  Treatment outcome and prognostic factors for primary nasal lymphoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  C. Ware,et al.  The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family , 1995, Cell.

[30]  E. Kieff,et al.  Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. , 1995, Immunity.

[31]  M. Rowe,et al.  Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers , 1994, Journal of virology.

[32]  D. Liebowitz Nasopharyngeal carcinoma: the Epstein-Barr virus association. , 1994, Seminars in oncology.

[33]  E. Kieff,et al.  Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Martine,et al.  Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. , 1993, The American journal of pathology.

[35]  E. Kieff,et al.  Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation , 1993, Journal of virology.

[36]  M. Fukuda,et al.  Detection of Epstein-Barr virus genome in natural-killer-like cell line, YT. , 1992, Leukemia.

[37]  E. Kieff,et al.  Induction of bcl-2 expression by epstein-barr virus latent membrane protein 1 protects infected B cells from programmed cell death , 1991, Cell.

[38]  U. Nater,et al.  Epstein-Barr virus. , 1991, The Journal of family practice.

[39]  E. Kieff,et al.  Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation , 1991, Journal of virology.

[40]  J. Martin,et al.  Immortalizing genes of Epstein-Barr virus. , 1991, Advances in virus research.

[41]  E. Kieff,et al.  Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23 , 1990, Journal of virology.

[42]  W. Hammerschmidt,et al.  Genetic analysis of immortalizing functions of Epstein–Barr virus in human B lymphocytes , 1989, Nature.

[43]  V. Baichwal,et al.  Posttranslational processing of an Epstein-Barr virus-encoded membrane protein expressed in cells transformed by Epstein-Barr virus , 1987, Journal of virology.

[44]  E. Kieff,et al.  Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus , 1986, Journal of virology.

[45]  E. Kieff,et al.  A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[46]  E. Kieff,et al.  Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein , 1984, Journal of virology.